Breast Cancer Studies Currently Recruiting Participants at the University of Chicago Medicine Comprehensive Cancer Center

Study Number Title
9127 Improved MRi Images of Breast Lesions (not all cancer patients)
Select
09-151-B A Pilot Study of Chemoprevention of Green Tea in Women with Ductal Carcinoma in Situ
15837A A Long Term Investigation of Curative Treatment in Breast Cancer Patients
10-136-A The Correlation of Radiographic Complete Response on Breast MRI with Pathologic Complete Response in Patients Receiving Neoadjuvant Systemic Treatment
Select
10-183-B Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and Molecular Analysis 2 (ISPY 2 Trial)
11365B Computer-Aided Diagnosis of Breast Lesions in Mammograms
Select
10-487-A The 1200 Patients Project: Studying the Implementation of Clinical Pharmacogenomic Testing
Select
11-0173 S1007:A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less
12-1229 Contralateral Prophylactic Mastectomy in Women Diagnosed with Ipsilateral Breast Cancer
12-1467 A Pilot Study Evaluating the Effects of Bariatric Surgery on Biomarkers of Breast Cancer Risk
12-2052 Improved Management of High Risk Breast Lesions with Quantitative MRI
Select
13-0418 S1207: Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-Risk, Hormone Receptor-Positive and Her2/Neu Negative Breast Cancer e3 Breast Cancer Study ¿ Evaluation Everolimus with Endocrine Therapy
Select
IRB13-0775 Validation of a Polygenic Neurotoxicity Risk Score in Patients with Unusually Severe Paclitaxel-Induced Neuropathy
Select
IRB13-1122 A Phase 2 Clinical Trial Assessing the Correlation of Early Chanages in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2- Positive Breast Cancer
Select
IRB13-1193 A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE) in Patients with Metastatic, GPNMB Over-Expressing, Triple-Negative Breast Cancer (The ¿METRIC¿ Study)
Select
IRB13-1337 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer
Select
IRB13-1365 A011202: A Randomized Phase III Trial Evaluating the Role of Axillary Lymph Node Dissection in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease After Neoadjuvant Chemotherapy
Select
IRB13-1389 Phase I Study of Mifepristone in Combination with Eribulin in Patients with Locally Advanced/Metastatic Breast or Ovarian Cancer with a Dose Expansion Cohort in Patients with Triple Negative Breast Cancer
Select
IRB14-0081 Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients with Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Select
IRB14-0283 A Randomized, Double-Blind, Phase 2 Study of Ruxolitinib or Placebo in Combination with Capecitabine in Subjects with Previously Treated Advanced or Metastatic HER2-negative Breast Cancer
Select
IRB14-0424 A Phase II Randomized Controlled Trial of Genomically Directed Therapy After Preoperative Chemotherapy in Patients with Triple Negative Breast Cancer
IRB14-0461 Development of High Spectral and Spatial Resolution (HiSS) MRI for Measurement of Breast Density
Select
IRB14-0701 A Phase 2, randomized, open-label, multicenter, safety and efficacy study of oral lucitanib in patients with FGF aberrant metastatic breast cancer
Select
IRB14-0105 A Phase I, Open-Label, Dose Escalation Study of MGA271 (Fc-optimized Humanized Anti-B7-H3 Monoclonal Antibody) in Patients with Refractory B7-H3-Expressing Neoplasms or Neoplasms whose Vasculature Expresses B7-H3
Select
IRB14-0194 A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer
Select
IRB14-0427 A Randomized, Placebo-Controlled, Double-Blind, Phase 3 Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects with Early Stage Triple Negative Breast Cancer (TNBC)
Select
IRB14-0712 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MPDL3280A Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors or Hematologic Malignancies
Select
CIRB14-0811 NRG-BR001: Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases
Select
CIRB14-0810 NSABP-B-51/RTOG 1304: A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy
Select
IRB14-0894 A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of MOXR0916 Administered Intravenously as a Single Agent to Patients with Locally Advanced or Metastatic Solid Tumors
Select
IRB14-0930 A Randomized, Multicenter, Open Label Study of MM-302 plus Trastuzumab vs. Chemotherapy of Physician’s Choice plus Trastuzumab in Anthracycline Naive Patients with Locally Advanced/Metastatic HER2-Positive Breast Cancer
Select
IRB14-0987 A First-in-Human Phase 1, Dose Escalation, Safety and Pharmacokinetic Study of PF-06647020 in Adult Patients with Advanced Solid Tumors
Select
IRB14-1375 A Phase III randomized, double-blind, placebo-controlled study of LEE011 or placebo in combination with tamoxifen and goserelin or a non-steroidal aromatase inhibitor (NSAI) and goserelin for the treatment of premenopausal women with hormone receptor positive, HER2-negative, advanced breast cancer
Select
CIRB14-1036 NSABP B-55/BIG 6-13: A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy
Select
IRB14-1253 Phase 2 Study of Single-Agent PF-03084014 in Patients with Advanced Triple-Negative Breast Cancer with or without Genomic Alterations in Notch Receptors
Select
IRB14-1429 A Phase 1 Study of MEDI4736 (Anti-PD-L1 Antibody) in Combination with Tremelimumab (Anti-CTLA-4 Antibody) in Subjects with Advanced Solid Tumor
Select
CIRB15-0239 NRG-BR002: A Phase IIR/III Trial of Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer

To learn more about cancer clinical trials or to make an appointment, call toll-free 1-855-702-8222 (adult trials) or 1-773-702-6808 (pediatric trials). Although our objective is to provide an updated listing of clinical trials, please note that a listing here does not guarantee that a trial is open or available to any specific patient. Additional trials may be available that are not listed. Complete information is available only from a treating physician.
Are you part of the research staff and cannot see your study listed here? Please contact the cancer center IT team